---
layout: post
title: "康方生物—B：IVONESCIMAB联合化疗治疗EGFR—TKI耐药的EGFR突变晚期非鳞状非小细胞肺癌（nsq—NSCLC）的III期临床试验完成首例患者给药"
date: 2022-01-31 07:19:42 +0800
categories: meirijingjixinwen
tags: 每日经济新闻新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/116.09926" data-code="09926|116|5" data-code2="09926|116|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=116.09926&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 09926_0" data-code="K 09926|116|5" data-code2="K 09926|116|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>每经AI快讯，康方生物—B:IVONESCIMAB联合化疗治疗EGFR—TKI耐药的EGFR突变晚期非鳞状非小细胞肺癌(nsq—NSCLC)的III期临床试验完成首例患者给药。<br /></p><center><img src="https://dfscdn.dfcfw.com/download/D25205680365194393184_w1100h896.jpg" style="border:#d1d1d1 1px solid;padding:3px;margin:5px 0;" /></center><p class="em_media">（文章来源：每日经济新闻）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202201312266948849>

[返回每日经济新闻新闻](//finews.withounder.com/category/meirijingjixinwen.html)｜[返回首页](//finews.withounder.com/)